Comparative Evaluation of β-Catenin and E-Cadherin Expression in Liquid Aspiration Biopsy Specimens of Thyroid Nodules

Исаева, А В; Зима, А. П.; Саприна, Т. В.; Kasoyan, K. T.; Попов, О. С.; Brynova, O. V.; Berezkina, I. S.; Васильева, О. А.; Ryazantseva, N. V.; Shabalova, Irena; Litvinova, L. S.; Pak, Yu. D.; Новицкий, В. В.

doi:10.1007/s10517-016-3397-z

Cited by 3 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liquid biopsies sample blood, saliva, or urine to look for circulating tumor cells, cell-free DNA, or extracellular vesicles (exosomes) that are released from the tumor [ 199 , 213 , 214 ]. Liquid biopsy is useful for differentiating FA from FTC, assessing the TME, early identification of metastases, and a de-differentiated FTC [ 163 , 199 , 212 , 215 , 216 ]. The existence of mutations such as the BRAF600E may be confirmed through a liquid biopsy done on the serum of a patient who has WDTC [ 199 ].…”

Section: Multi-omics Of Follicular Carcinoma and Other Thyroid Tumorsmentioning

confidence: 99%

Multi-Omics and Management of Follicular Carcinoma of the Thyroid

et al. 2023

View full text Add to dashboard Cite

Follicular thyroid carcinoma (FTC) is the second most common cancer of the thyroid gland, accounting for up to 20% of all primary malignant tumors in iodine-replete areas. The diagnostic work-up, staging, risk stratification, management, and follow-up strategies in patients who have FTC are modeled after those of papillary thyroid carcinoma (PTC), even though FTC is more aggressive. FTC has a greater propensity for haematogenous metastasis than PTC. Furthermore, FTC is a phenotypically and genotypically heterogeneous disease. The diagnosis and identification of markers of an aggressive FTC depend on the expertise and thoroughness of pathologists during histopathological analysis. An untreated or metastatic FTC is likely to de-differentiate and become poorly differentiated or undifferentiated and resistant to standard treatment. While thyroid lobectomy is adequate for the treatment of selected patients who have low-risk FTC, it is not advisable for patients whose tumor is larger than 4 cm in diameter or has extensive extra-thyroidal extension. Lobectomy is also not adequate for tumors that have aggressive mutations. Although the prognosis for over 80% of PTC and FTC is good, nearly 20% of the tumors behave aggressively. The introduction of radiomics, pathomics, genomics, transcriptomics, metabolomics, and liquid biopsy have led to improvements in the understanding of tumorigenesis, progression, treatment response, and prognostication of thyroid cancer. The article reviews the challenges that are encountered during the diagnostic work-up, staging, risk stratification, management, and follow-up of patients who have FTC. How the application of multi-omics can strengthen decision-making during the management of follicular carcinoma is also discussed.

show abstract

Section: Multi-omics Of Follicular Carcinoma and Other Thyroid Tumorsmentioning

confidence: 99%

Multi-Omics and Management of Follicular Carcinoma of the Thyroid

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Once activated by proteins upstream in the pathway, β-catenin is able to accumulate in the cytoplasm and eventually is translocated into the nucleus. In the nucleus, the protein works with T-cell factor/lymphoid enhancing factor (TCF/LEF) to modulate gene expression ( 8 , 9 ).…”

Section: Molecular Markers Of Thyroseq Next-generation Sequencing Panmentioning

confidence: 99%

A Concise Atlas of Thyroid Cancer Next-Generation Sequencing Panel ThyroSeq v.2

Alsina¹,

Alsina²,

Güleç

2017

Mirt

View full text Add to dashboard Cite

The next-generation sequencing technology allows high out-put genomic analysis. An innovative assay in thyroid cancer, ThyroSeq® was developed for targeted mutation detection by next generation sequencing technology in fine needle aspiration and tissue samples. ThyroSeq v.2 next generation sequencing panel offers simultaneous sequencing and detection in >1000 hotspots of 14 thyroid cancer-related genes and for 42 types of gene fusions known to occur in thyroid cancer. ThyroSeq is being increasingly used to further narrow the indeterminate category defined by cytology for thyroid nodules. From a surgical perspective, genomic profiling also provides prognostic and predictive information and closely relates to determination of surgical strategy. Both the genomic analysis technology and the informatics for the cancer genome data base are rapidly developing. In this paper, we have gathered existing information on the thyroid cancer-related genes involved in the initiation and progression of thyroid cancer. Our goal is to assemble a glossary for the current ThyroSeq genomic panel that can help elucidate the role genomics play in thyroid cancer oncogenesis.

show abstract

E-cadherin expression is associated with susceptibility and clinicopathological characteristics of thyroid cancer

2019

View full text Add to dashboard Cite

Background: Recently, many studies have been carried out to investigate the clinicopathological significance of E-cadherin expression in thyroid cancer. However, the results remained inconsistent. In the present study, we performed a meta-analysis to evaluate the associations of E-cadherin expression with susceptibility and clinicopathological characteristics of thyroid cancer. Methods: Eligible studies were searched from Medicine, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang databases. The strength of associations between E-cadherin expression and susceptibility and clinicopathological features of thyroid cancer were assessed by pooled odds ratios (ORs) and 95% confidence intervals (CIs). Results: Forty-six studies with 1700 controls and 2298 thyroid cancer patients were included for this meta-analysis. Pooled results indicated that E-cadherin expression was significantly associated with susceptibility of papillary cancer and follicular cancer (papillary cancer, ORs = 14.31, 95% CIs = 3.42–59.90; follicular cancer, ORs = 10.14, 95% CI = 4.52–22.75). Significant association between E-cadherin expression and thyroid cancer risk was also observed in the subgroup analysis based on control group (normal thyroid tissue, ORs = 28.28, 95% CI = 8.36–95.63; adjacent thyroid tissue, ORs = 8.83, 95% CI = 3.27–23.85; benign thyroid tissue, ORs = 43.96, 95% CI = 9.91–194.95). In addition, E-cadherin expression was significantly correlated with lymph node metastasis, differentiation, and tumor-node-metastasis (TNM) stage of thyroid cancer (lymph node metastasis, ORs = 3.21, 95% CI = 1.98–5.20; differentiation, ORs = 0.25, 95% CI = 0.07–0.82; TNM stage, ORs = 4.85, 95% CI = 2.86–8.25). Conclusions: The present study showed that E-cadherin expression was significantly associated with susceptibility and clinicopathological characteristics of thyroid cancer, which suggested that E-cadherin expression might be a potential predictive factor for clinical progression of thyroid cancer.

show abstract

Comparative Evaluation of β-Catenin and E-Cadherin Expression in Liquid Aspiration Biopsy Specimens of Thyroid Nodules

Cited by 3 publications

References 14 publications

Multi-Omics and Management of Follicular Carcinoma of the Thyroid

Multi-Omics and Management of Follicular Carcinoma of the Thyroid

A Concise Atlas of Thyroid Cancer Next-Generation Sequencing Panel ThyroSeq v.2

E-cadherin expression is associated with susceptibility and clinicopathological characteristics of thyroid cancer

Contact Info

Product

Resources

About